Safety Concerns Related to Global Biosimilars Drug Development

Posted 24 June 2014 By Raymond A. Huml, MS, DVM, RAC, Nigel Rulewski, MD, DCH, DRCOG

placeholder+image An initial unfortunate experience in the late 1990s served as an alert to the inherent risks of making apparently small changes to a biological product. 

Share this article:

Categories: Biologics and biotechnology, Clinical, Postmarket surveillance

Tags: Biosimilars, Biosimilarity, Biosimilar Safety, Safety of Biosimilars

Regulatory Exchange: Latest Updates From the Community